목적 : Hydroxyapatite와 MedporⓇ 안와 충전물 삽입술의 장기간 임상결과를 알아보고자 하였다. 대상과방법 : 1992년 1월부터 2002년 12월까지 본원 안과에서 Hydroxyapatite를 삽입한 108안과 MedporⓇ를 삽입한 82안을 대상으로 하였으며, 수술 방법에 따라 발생한 합병증의 종류와 빈도, 발생시기 및 처치에 대해서 비교하였다. 결과 : Hydroxyapatite 삽입군은 술 후 14개월∼10년(평균 57.6개월)간 경과 관찰하였고, 충전물의 노출이 14안(13%), 연부조직 합병증이 27안(25%), 안검 합병증이 30안(27.8%), Peg 삽입으로 인한 합병증이 21안(27.3%)에서 발생하였다. MedporⓇ 삽입군은 술 후 5개월∼4년(평균 18.6개월)간 경과 관찰하였고, 충전물의 노출이 5안(6.1%), 연부조직 합병증이 14안(17.1%), 안검 합병증이 25안(30.5%), MCP 삽입으로 인한 합병증이 3안(16.7%)에서 발생하였다. 결론 : Hydroxyapatite와 MedporⓇ 안와 충전물 모두 초기에 발생한 합병증에 대한 적극적인 치료와 술 후 몇 년이 지난 후에 늦게 발생하는 합병증에 대한 장기간의 추적관찰이 중요할 것으로 사료된다.

Purpose: This study was conducted to determine long-term results of Hydroxyapatite and MedporⓇ ocular implants. Methods: This study was done on 108 eyes inserted with hydroxyapatite ocular implant and 82 eyes inserted with MedporⓇ ocular implant that were treated at the present hospital from January 1992 to December 2002. We compared the types, frequencies, and onset and treatment of complications according to the types of surgery. Results: The clinical outcome for 14 months to 10 years (average: 57.6 months) was examined in the hydroxyapatite implantation group. The complications were implant exposure in 14 eyes (13%), soft tissue complication in 27 (25%), eyelid complication in 30 (27.8%), and complication due to Peg insertion in 21 (27.3%). The clinical outcome for 5 months to 4 years (average: 18.6 months) was examined in the MedporⓇ implant group. The complications involved were implant exposure in 5 eyes (6.1%), soft tissue complication in 14 (17.1%), eyelid complication in 25 (30.5%), and complication due to MCP insertion in 3 (16.7%). Conclusions: Active treatment for early complications and long-term follow-up for late complications are needed with hydroxyapatite and MedporⓇ implantations.

Purpose: This study was conducted to determine long-term results of Hydroxyapatite and MedporⓇ ocular implants. Methods: This study was done on 108 eyes inserted with hydroxyapatite ocular implant and 82 eyes inserted with MedporⓇ ocular implant that were treated at the present hospital from January 1992 to December 2002. We compared the types, frequencies, and onset and treatment of complications according to the types of surgery. Results: The clinical outcome for 14 months to 10 years (average: 57.6 months) was examined in the hydroxyapatite implantation group. The complications were implant exposure in 14 eyes (13%), soft tissue complication in 27 (25%), eyelid complication in 30 (27.8%), and complication due to Peg insertion in 21 (27.3%). The clinical outcome for 5 months to 4 years (average: 18.6 months) was examined in the MedporⓇ implant group. The complications involved were implant exposure in 5 eyes (6.1%), soft tissue complication in 14 (17.1%), eyelid complication in 25 (30.5%), and complication due to MCP insertion in 3 (16.7%). Conclusions: Active treatment for early complications and long-term follow-up for late complications are needed with hydroxyapatite and MedporⓇ implantations.

Complication, Hydroxyapatite, Medpor